Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis.
Junji Akagi, Hideo Baba · Oncology reports · 2019
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 55 patients, hydrogen gas decreased the abundance of exhausted terminal PD‐1+ CD8+ T cells, increased that of active terminal PD‐1‐ CD8+ T cells, and improved PFS and OS times, suggesting that the balance between terminal PD1+ and PD1‐ CD8+ T cells is critical for cancer prognosis. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 55 patients. Hydrogen gas decreased the abundance of exhausted terminal PD‐1+ CD8+ T cells, increased that of active terminal PD‐1‐ CD8+ T cells, and improved PFS and OS times, suggesting that the balance between terminal PD1+ and PD1‐ CD8+ T cells is critical for cancer prognosis.
What the Researchers Studied
The researchers studied 55 patients. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
The patients inhaled hydrogen gas for 3 h/day at their own homes and received chemotherapy at the Tamana Regional Health Medical Center (Tamana, Kumamoto, Japan). Hydrogen gas decreased the abundance of exhausted terminal PD‐1+ CD8+ T cells, increased that of active terminal PD‐1‐ CD8+ T cells, and improved PFS and OS times, suggesting that the balance between terminal PD1+ and PD1‐ CD8+ T cells is critical for cancer prognosis. The authors concluded that the present results suggested that hydrogen gas reverses imbalances toward PD‐1+ CD8+ T cells to provide an improved prognosis.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 55 patients. The reported sample size was 55. The study used a human clinical study. The hydrogen delivery method was inhaled hydrogen gas.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.